Seven Jackpots
10 Cric
Guide 2 Gambling

MLSU- VC reaches NCC Headquarters

( Read 5871 Times)

15 Jan, 21 11:04
Share |
Print This Page

MLSU- VC reaches NCC Headquarters

Udaipur: Vice-Chancellor Professor Amarika Singh himself reached NCC headquarters in Jaipur on Monday to start National Cadet Corps (NCC) branches in all constituent colleges at Mohanlal Sukhadia University.Vice-Chancellor Prof Singh met senior NCC officials and said that at Mohanlal Sukhadia University, NCC activities are currently conducted only in Science College. Students of Commerce, Arts, Law, and Management cannot take NCC as it does not have units in the respective colleges. There was also a long-standing demand of the students that units of NCC be started in all colleges. In this regard, Vice-Chancellor Professor Amarika Singh reached NCC headquarters in Jaipur on Monday and met NCC Director Lt Col Dr. PS Rathore and apprised them about it. After talking to the Vice-Chancellor Professor in Colonel Rathore, he assured me that he would arrange to start the NCC unit in all the colleges soon after negotiating at the departmental level, preparing the proposal. Press Statement on Restricted Emergency approval of COVID-19 virus vaccine The Subject Expert Committee of Central Drugs Standard Control Organisation (CDSCO) met on 1st and 2nd January, 2021 and made recommendations in respect of proposal for Restricted Emergency Approval of COVID-19 virus vaccine of M/s Serum Institute of India and M/s Bharat Biotech as well as Phase III clinical trial of M/s Cadila Healthcare Ltd. The Subject Expert Committee consists of domain knowledge experts from the fields of pulmonology, immunology, microbiology, pharmacology, paediatrics, internal medicine, etc. M/s Serum Institute of India, Pune has presented a Recombinant Chimpanzee Adenovirus vector vaccine (Covishield) encoding the SARS-CoV-2 Spike (S) glycoprotein with technology transfer from AstraZeneca/Oxford University. The firm submitted safety, immunogenicity and efficacy data generated on 23,745 participants aged ≥ 18 years or older from overseas clinical studies. The overall vaccine efficacy was found to be 70.42%. Further, M/s Serum was granted permission to conduct Phase-II/III clinical trial on 1600 participants within the country. The firm also submitted the interim safety and immunogenicity data generated from this trial and the data was found comparable with the data from the overseas clinical studies. After detailed deliberations Subject Expert Committee has recommended for the grant of permission for restricted use in emergency situation subject to certain regulatory conditions. The clinical trial ongoing within the country by the firm will continue.M/s Bharat Biotech has developed a Whole Virion Inactivated Corona Virus Vaccine (Covaxin) in collaboration with ICMR and NIV (Pune), from where they received the virus seed strains. This vaccine is developed on Vero cell platform, which has well established track record of safety and efficacy in the country & globally.The firm has generated safety and immunogenicity data in various animal species such as mice, rats, rabbits, Syrian hamster, and also conducted challenge studies on non-human primates (Rhesus macaques) and hamsters. All these data has been shared by the firm with CDSCO. Phase I and Phase II clinical trials were conducted in approx.800 subjects and the results have demonstrated that the vaccine is safe and provides a robust immune response. The Phase III efficacy trial was initiated in India in 25,800 volunteers and till date, ~22,500 participants have been vaccinated across the country and the vaccine has been found to be safe as per the data available till date.

Source :

यह खबर निम्न श्रेणियों पर भी है: Udaipur News
Your Comments ! Share Your Openion